|
Sl. No.
|
Name of the applicant
|
Gist of the proposal
|
Proposed amount of FDI (in Rs. Crore)
|
Sector
|
|
1
|
M/s
Bharti Shipyard Ltd., Mumbai
(No.187/2011-FC.I)
|
M/s Bharati Shipyard Limited, Mumbai (Investee
Company) which has existing FII and NRI investments has proposed to undertake
additional defence activities along with its existing activities.
|
Nil
|
Defence
|
|
2
|
M/s
Solar Industries India Limited, Nagpur
(No.
86/2014-FC.I)
|
M/s Solar Industries Limited, which has
minimal investment FII/NRI investment, has sought approval for undertaking
additional activity of manufacturing defence products.
|
Nil
|
Defence
|
|
3
|
M/s
Hatsoff Helicopter Training Pvt Ltd, Bangalore (No. 112/2014-FC.I)
|
Post facto approval has been sought by M/s
Hatsoff Helicopter Training Pvt Ltd for the issue of shares against interest
money accrued on the foreign remittance received by it from the foreign
investor.
|
Rs.
5.6 Crore
|
Civil
Aviation
|
|
4
|
M/s
Verizon Communications India Private Limited
[No.
FC.II – 39/2002]
|
M/s Verizon Communications India Private
Limited, engaged in telecom sector, is seeking approval to increase foreign
equity participation by its foreign parent from 74% to 100%.
|
Rs.
2.32 Crore
|
Telecom
|
|
5
|
M/s
Ironman Media and Advisory Services Private Ltd. (No. 11/SIA/NFC/2014)
|
M/s Ironman Media and Advisory Services
Private Ltd. has sought approval to issue shares for the amount received as
FDI.
|
Rs.
0.30 Crore
|
Print Media
|
|
6
|
M/s
Axes Studios LLP
(No.10/SIA/NFC/2014-FC
I)
|
M/s Axes Studios LLP has sought approval to
accept NRI investment from Mr. Gunjan Dhirendra Chag, NRI, UK.
|
Rs.
0.99 Crore
|
IT
|
|
7
|
M/s
MapfreAsistencia Camp A+ Aa International de SegurosYReaseguros, SA(No.
245/2013-FC.I)
|
Permission for incorporating a WoS in India
for providing software related services and also act as Corporate Agent to an
Indian Insurer by Soliciting and Procuring Insurance business as Corporate
Agent.
|
Rs.
1.70 Crore (US$ 0.275 million)
|
Insurance
|
|
8
|
M/s
Instant Global Money Transfer Private Limited
(No.
78/2014-FC.I)
|
M/s Instant Global Money transfer Private
Limited, Punjab is seeking post facto approval for partly paid shares issued
to the M/s Trans-Fast Remittance LLC, New York against FDI.
|
Rs.
0.15 Crore
|
NBFC
|
|
9
|
M/s
GETCO Asia Pte. Ltd., Singapore
(No.
FC.II: 156/2011)
|
Approval sought by a wholly foreign owned
company for setting up a downstream subsidiary to be engaged in the business
of commodities broking, commodities trading and providing liquidity to the
commodities market.
|
Nil
|
NBFC
|
|
10
|
M/s
Equitas Holdings Private Limited, Tamil Nadu
(No.
FC.II- 236/2011)
|
Approval has been sought by M/s Equitas
Holdings Private Limited for downstream investment in its wholly owned
subsidiaries by its existing and new foreign shareholders hereby increasing
the foreign equity from 91.30% to 93.12%
|
Rs.
325 Crore
|
Investing
Company
|
|
11
|
M/s
ANZCapital Pvt. Ltd. (FC.II: 121/2001)
|
M/s ANZ Capital Private Limited is seeking
approval for removal of the condition prescribed in the FC approval.
|
Nil
|
NBFC
|
|
12
|
M/s
Medipass SRL, Italy
(No.
83/2014-FC.I)
|
Approval is sought by Medipass SRL, an Italian
company for the acquisition of 85.19% stake in the share capital of M/s
Clearview Healthcare Private Limited, an investing company with downstream
investment in health sector.
|
Rs.
15.11 Crore
|
Pharma
|
|
13
|
M/s
Intas Pharmaceuticals Limited, Ahmedabad
[No.
FC.II – 334/2005]
|
M/s Intas Pharmaceuticals Limited, an Indian
pharmaceuticals company, seeking approval for NR to NR transfer of 10.16% its
shares.
|
Nil
|
Pharma
|
|
14
|
M/s.
Koye Pharmaceutical Private Limited
(No.
41/2014-FC.I)
|
M/s Koye Pharmaceuticals Private Limited, a
brownfield Pharmaceuticals company, has sought permission to issue additional
1,818 CCPS, 15constituting up to 6.81% of the share capital of the company on
a post-issuance and fully diluted basis, to the already existing investor M/s
SCI Growth Investments II, Mauritius.
|
Rs.
7.50 Crore
|
Pharma
|
|
15
|
M/s
Amneal Pharmaceuticals Company India Pvt. Ltd.
(No.
67/2014-FC-I)
|
M/s Amneal Pharmaceuticals Company Private
Limited, a foreign owned and controlled company, is seeking approval for
acquisition of entire share capital of Epsilon, through a share purchase
agreement a company engaged in trading of generic pharma products and in
process of setting up formulation manufacturing facility.
|
UptoRs.
205 Crore
|
Pharma
|
|
16
|
M/s
Fresenius Kabi Oncology Limited, New Delhi
(No.
89/2014-FC.I)
|
Approval
has been sought for issuance of equity shares for an aggregate consideration
of Rs. 119 Crore to increase foreign shareholding from 96.22% to 96.483% of
its parent company.
|
Rs.
119 Crore
|
Pharma
|
|
17
|
M/s
Ferring Pharmaceuticals Pvt. Ltd.
(FC.II
456/1996)
|
M/s Ferring Pharmaceuticals Private Limited is
seeking post facto approval for the investment made by Ferring BV (foreign
company) into M/s Ferring Pharmaceuticals Pvt. Ltd for onward downstream
investment in its WoS M/s Ferring Therapeutics Pvt. Ltd., prior to approval
of FIPB.
|
Nil
|
Pharma
|
|
18
|
M/s Indusind Bank Ltd. (591/FC/93/NRI-FC I)
|
the applicant has sought approval for increase
in foreign investment in IBL to 74% with a specific request to grant
post-facto approval for increase in foreign holding from 68.51% to 72.07% on
30.06.2014
|
Not
indicated
|
Banking –
Private Sector
|
|
19
|
M/s
Dymak India Services Limited Liability Partnership, Uttar Pradesh
(No.
85/2014-FC.I)
|
Post Facto approval has been sought by M/s
Dymak India Services LLP for foreign contribution of Rs. 44,53,523 to acquire
80% stake in the Indian LLP by M/s Dymak A/S CVR 1975 7803.
|
Nil
|
Whole Sale
Trading
|
|
20
|
M/s
Tara India Fund IV Trust, Mumbai
(No.
102/2014-FC.I)
|
M/s Tara India Fund IV Trust seeking
permission for investment upto US$45 million by subscribing to the units of
the applicant and category B investors to invest up to US $ 5 million in the
units of TARA Fund.
|
Rs
305.63 Crore
(US$
50 million)
|
Investing
Company
|
|
Sl. No.
|
Name of the applicant
|
Gist of the proposal
|
Sector
|
|
1
|
M/s
Pureplay Investment Partners, Mauritius
(No.
FC.I-270/2013)
|
Proposal
for FDI by M/s Pureplay Investment Partners Mauritius in:
(a)
upto 74% in M/s Indiverse Broadband Private Limited, an existing company
engaged in the cable television networks business and undertaking up
-gradation of networks towards digitization and addressability (b) 49% in
(JVC-I) and 49% in (JVC-2) (both JVC will be act as investing company).
|
Telecom
|
|
2
|
M/s ASV
Europa Security Private Limited, Secunderabad (No. 91/2014-FC.I)
|
M/s
ASV Europa Security Private Limited, Secunderabad seeking permission for
receiving 49% foriegn investment in Security Services and Man Power
recruitment & training services by way of transfer of shares from its
current Indian Shareholder.
|
Private
Security Agencies
|
|
3
|
M/s Halyard
Health Inc., USA (No. 109/2014-FC.I)
|
Approval
has been sought by M/s Halyard Health, Inc, USA, WoS of Kimberley Clark group
to set up a new company in India to be engaged in import and sale of
healthcare products on “Wholesale business” and transfer of some assets from
one WoS to the new company.
|
Pharma
|
|
4
|
M/s
BeloorBayir Biotech Limited, Bangalore (No. 111/2014-FC.I)
|
M/s
BeloorBayir Biotech Limited Bangalore, with 22.55% foreign investment (on a
fully diluted basis) by M/s India Agri Business Fund Ltd. Mauritius proposes
to acquire, by way of merger, the entire share capital of M/s Bayir Chemicals
India Private Limited, Bangalore and M/s Sneha Nutura India Private Limited,
both companies being engaged in pharmaceuticals sector.
|
Pharma
|
|
5
|
Mr. Anurag
Kumar (No. 12/SIA/NFC/2014)
|
The
applicant has sought Government approval for acquisition of 100% equity of
BPPL. The proposal has been supported by the consent of existing
shareholders and Board Resolution of the investee company.
|
Pharma
|
|
6
|
M/s
Tevapharm India Pvt. Ltd. [FC.II 35(2001)/45(2001)]
|
A
100% foreign owned Indian brownfield pharma company is seeking approval for
additional capital infusion.
|
Pharma
|
|
7
|
M/s GMU
InfosoftPvt. Ltd.
(No.
17/SIA/NFC/2011-FC I)
|
company
proposes to issue 2750 equity shares (1.52% equity) of Rs.10/each, to Mr.
Ramneet Singh Rekhi, USA, NRI and 2750 equity shares (1.52% equity) of
Rs.10/each to Mr.Sartaj Singh Rekhi, USA, NRI.
|
Others
|
|
8
|
M/s U
InfosoftPvt. Ltd. ( No. 16/SIA/NFC/2011-FC I)
|
The
company proposes to issue 2750 equity shares (1.52% equity) of Rs.10/each, to
Mr. Ramneet Singh Rekhi, USA, NRI and 2750 equity shares (1.52% equity) of
Rs.10/each to Mr.Sartaj Singh Rekhi, USA, NRI.
|
Others
|
|
Sl. No.
|
Name of the applicant
|
Gist of the proposal
|
Sector
|
|
1
|
M/s
Indus Teqsite Private Limited, Tamil Nadu
(No.
261/2013-FC.I)
|
A JV is proposed to be formed with 26% FDI to
undertake defence sector activities.
|
Defence
|
|
2
|
M/s.
Sistema Shyam Teleservices Ltd.
[FC.II
241 (07)/285(07)]
|
Increases in FDI upto 100% in M/s Sistema
Shyam Tele Services Limited and its downstream WoS M/s Shyam Internet
Services Limited, both engaged in telecom sector, on account of conversion of
Redeemable Preference Shares into equity.
|
Telecom
|
|
3
|
M/s
Kusum Healthcare Private Limited, New Delhi
(No.
92/2014-FC.I)
|
M/s Kusum Healthcare Private Limited, New
Delhi, engaged in pharmaceuticals sector, has sought approval for issuing
equity shares/CCPS/CCDs to M/s Upasa Holdings AG, Switzerland, leading to 25%
shareholding in the applicant.
|
Pharma
|
|
4
|
M/s
BioMerieux India Private Limited, New Delhi
(No.
97/2014-FC.I)
|
M/s BioMerieux India Pvt Ltd., a WoS of M/s
BioMerieux France has sought approval for additional downstream investment of
10% (increase from 60% to 70%) in M/s RAS Life sciences Private Limited, a
company engaged in brownfield pharmaceutical sector. Post-facto approval for
initial investment of 60% would also be required.
|
Pharma
|
|
5
|
M/s
HBM Private Equity India
(No.
216/2013-FC.I)
|
Approval has been sought by M/s HBM Private
Equity India, Mauritius to acquire 7.72% equity shares of M/s Marck
biosciences Ltd from IFCI Venture Capital Fund Ltd. This will result in
increased foreign equity participation from 49.29% to 57.01%. However there
is no change in the holding of the promoter group (80.01%).
|
Pharma
|